ANGPTL3 and inflammatory bowel disease: Specifically, genetically proxied ANGPTL3 inhibition demonstrated a significant association with an increased risk of IBD (OR = 1.846; P-adjusted = 0.006) and CD (OR = 3.709; P-adjusted = 2.48 × 10−6), respectively.